Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Hepatitis C Virus Infection Clinical Trial

Official title:

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02994056
• Other study ID #: GS-US-342-4022
• Secondary ID: 2016-003066-10
• Status: Completed
• Phase: Phase 2
• Start date: January 23, 2017
• Est. completion date: December 12, 2018

Study information

• Verified date: September 2019
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection and Child-Pugh-Turcotte (CPT) Class C cirrhosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: December 12, 2018
• Est. primary completion date: September 25, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• A body mass index (BMI) of = 18 kg/m^2

• Chronic HCV infection (= 6 months) as documented by either prior medical history or liver biopsy

• Quantifiable HCV RNA at screening

• Individuals may be non-transplanted or with recurrent HCV post-liver transplant.

• If listed for liver transplant, then the projected date of transplant must be =12 weeks after Day1 of treatment

• If post-liver transplant, then Day1 must be = 6 months from date of transplant

• CPT score of 10 to 12, inclusive, as determined at screening

• Liver imaging within 6 months of Day 1 to exclude hepatocellular carcinoma (HCC)

• If treatment-experienced, the most recent HCV treatment must have been completed at least 8 weeks prior to Screening

• Females of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 prior to randomization

• Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception

• Females must agree to refrain from egg donation and in vitro fertilization during treatment until at least 30 days after the last dose of SOF/VEL or 6 months after the last dose of RBV, whichever occurs last

• Lactating females must agree to discontinue nursing before the study drugs are administered

• Males must agree to refrain from sperm donation from the date of screening until at least 7 months after the last dose of RBV or 30 days after the last dose of SOF/VEL, whichever occurs last

• Adults must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments

Key Exclusion Criteria:

• Current or prior history of any of the following:

• Clinically significant medical or psychiatric illness or individual is currently under evaluation for a potentially clinically significant illness

• Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug

• Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy

• Significant pulmonary disease, significant cardiac disease or porphyria

• Malignancy within the 5 years prior to screening, with the exception of specific cancers that have been cured by surgical resection (basal cell skin cancer, etc.). Adults under evaluation for possible malignancy are not eligible

• Significant drug allergy (such as anaphylaxis or hepatotoxicity)

• Any history of organ transplant other than liver or kidney

• Chronic liver disease of a non-HCV etiology

• Inability to exclude HCC by imaging within 6 months of Day 1

• Alpha-fetoprotein (AFP) > 50 unless negative imaging for hepatic masses within the last 6 months or during screening

• Active spontaneous bacterial peritonitis at screening

• Infection requiring systemic antibiotics at the time of screening

• Evidence of fibrosing cholestatic hepatitis at screening

• Life threatening serious adverse event (SAE) during screening

• Active variceal bleeding within 6 months of screening

• Prior placement of a portosystemic shunt (such as TIPS)

• ECG with clinically significant abnormalities

• Laboratory parameters with clinically significant abnormalities

• Hepatitis B surface antigen positive at screening

• Infection with human immunodeficiency virus (HIV)

• Clinically-relevant alcohol or drug abuse within 12 months of screening. A positive drug screen will exclude individuals unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved by the Investigator

• Prior exposure to any HCV Non-structural Protein 5A (NS5A) inhibitor

• Current use of corticosteroids at any dose >10 mg of prednisone/day (or equivalent dose of corticosteroid)

• Use of any prohibited concomitant medications

• Use of granulocyte macrophage colony-stimulating factor (GM-CSF), epoetin alfa or other hematopoietic stimulating agents within 2 weeks of screening

• Male with pregnant female partner

• History of clinically significant hemoglobinopathy (eg, sickle cell disease, thalassemia)

• Contraindications to RBV therapy

• Known hypersensitivity to VEL, RBV, SOF, the metabolites, or formulation excipients

• Participation in a clinical study with an investigational drug or biologic within 3 months prior to Day 1

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Related Conditions & MeSH terms

• Communicable Diseases
• Hepatitis C
• Hepatitis C Virus Infection
• Infection
• Virus Diseases

Intervention

Drug:
• SOF/VEL
400/100 mg FDC tablet administered orally once daily
• RBV
Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.

Locations

Country	Name	City	State
France	Hopital Henri Mondor	Créteil
France	Hopital Paul Brousse	Villejuif
United States	Digestive Disease Associates, PA	Catonsville	Maryland
United States	Northwestern Memorial Hospital; Clinical Research Unit	Chicago	Illinois
United States	Southern Therapy and Advanced Research LLC	Jackson	Mississippi
United States	Intermountain Liver Disease and Transplant Center	Murray	Utah
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania
United States	Bon Secours St. Mary's Hospital of Richmond, Inc. d/b/a Bon Secours Liver Institute of Virginia	Richmond	Virginia
United States	American Research Corporation at Texas Liver Institute	San Antonio	Texas
United States	University of Washington/ Harborview Medical Center	Seattle	Washington
United States	Tampa General Medical Group	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Gilead Sciences

Countries where clinical trial is conducted

United States,  France, 

References & Publications (1)

Flamm S, Lawitz E, Borg B, Charlton M, Landis C, Reddy R, et al. High Efficacy and Improvement in CPT Class With Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients With CPT C Decompensated Cirrhosis [Poster THU-138]. EASL: The International Li

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)	SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.	Posttreatment Week 12
Primary	Percentage of Participants Who Permanently Discontinued Study Drug (SOF/VEL or RBV) Due to an Adverse Event		First dose date up to Week 12
Secondary	Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4)	SVR4 was defined as HCV RNA < LLOQ 4 weeks after stopping study treatment.	Posttreatment Week 4
Secondary	Percentage of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24)	SVR24 was defined as HCV RNA < LLOQ at 24 weeks after stopping study treatment.	Posttreatment Week 24
Secondary	Percentage of Participants With HCV RNA < LLOQ While on Study Treatment		Weeks 2, 4, 8, and 12
Secondary	Percentage of Participants With No Change, Improved, and Worsened Child-Pugh-Turcotte (CPT) Class	CPT is a chronic liver disease classification system. Classes include CPT Class A, CPT Class B, and CPT Class C, in order of greater disease severity. Participants with improved CPT class was defined as having Class C at Baseline and Class B or A at Posttreatment Week 24 or Class B at Baseline and Class A at Posttreatment Week 24. Participants with worsened CPT class was defined as having Class A at Baseline and Class B or C at Posttreatment Week 24 or Class B at Baseline and Class C at Posttreatment Week 24. Participants with no change CPT class was defined as having CPT Class same between Baseline and Posttreatment Week 24.	Baseline to Posttreatment Week 24
Secondary	Percentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score	MELD score is a chronic liver disease severity scoring system. Scores can range from 6 to 40, with higher scores indicating greater disease severity. "No change" was assigned for differences (posttreatment visits minus baseline score) of -1, 0 or 1; "Decrease" was assigned for differences that were less than or equal to -2; and "Increase" was assigned for values that were greater than or equal to 2.	Baseline to Posttreatment Week 24
Secondary	Absolute HCV RNA Level Through Week 12		Baseline; Weeks 2, 4, 8, and 12
Secondary	Change From Baseline in HCV RNA		Baseline; Weeks 2, 4, 8, and 12
Secondary	Number of Participants With Virologic Failure	Virologic failure was defined as: On-treatment virologic failure: Breakthrough (confirmed HCV RNA = LLOQ after having previously had HCV RNA < LLOQ while on treatment), or; Rebound (confirmed > 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or; Non-response (HCV RNA persistently = LLOQ through 8 weeks of treatment); Virologic relapse: Confirmed HCV RNA = LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at last on-treatment visit	Baseline up to Posttreatment Week 24